Vanguard Group
BLCM

Vanguard Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Vanguard Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,309
Closed -$21.9K – 4600
2023
Q1 		$21.9K Sell
66,309
-115,534
-64% -$107K ﹤0.01% 4525
2022
Q4 		$131K Sell
181,843
-182,877
-50% -$181K ﹤0.01% 4362
2022
Q3 		$437K Hold
364,720
– – ﹤0.01% 4250
2022
Q2 		$434K Hold
364,720
– – ﹤0.01% 4323
2022
Q1 		$788K Sell
364,720
-65,358
-15% -$106K ﹤0.01% 4282
2021
Q4 		$640K Hold
430,078
– – ﹤0.01% 4378
2021
Q3 		$1.26M Buy
430,078
+5,767
+1% +$17.6K ﹤0.01% 4193
2021
Q2 		$1.4M Buy
424,311
+223,524
+111% +$717K ﹤0.01% 4072
2021
Q1 		$755K Buy
200,787
+32,022
+19% +$139K ﹤0.01% 4063
2020
Q4 		$596K Sell
168,765
-5,238
-3% -$22.1K ﹤0.01% 3927
2020
Q3 		$1.14M Sell
174,003
-2,353
-1% -$16K ﹤0.01% 3627
2020
Q2 		$1.31M Sell
176,356
-11,924
-6% -$81.2K ﹤0.01% 3543
2020
Q1 		$887K Buy
188,280
+10,387
+6% +$112K ﹤0.01% 3521
2019
Q4 		$2.29M Hold
177,893
– – ﹤0.01% 3411
2019
Q3 		$1.87M Sell
177,893
-9,840
-5% -$129K ﹤0.01% 3470
2019
Q2 		$3.19M Sell
187,733
-35,375
-16% -$957K ﹤0.01% 3324
2019
Q1 		$7.52M Buy
223,108
+27,486
+14% +$919K ﹤0.01% 2976
2018
Q4 		$5.71M Buy
195,622
+838
+0.4% +$37.2K ﹤0.01% 3029
2018
Q3 		$12M Buy
194,784
+2,341
+1% +$158K ﹤0.01% 2828
2018
Q2 		$14.2M Buy
192,443
+57,513
+43% +$4.48M ﹤0.01% 2728
2018
Q1 		$8.85M Sell
134,930
-1,206
-0.9% -$91.1K ﹤0.01% 2879
2017
Q4 		$11.4M Buy
136,136
+14,908
+12% +$1.46M ﹤0.01% 2754
2017
Q3 		$14M Buy
121,228
+584
+0.5% +$61.4K ﹤0.01% 2654
2017
Q2 		$14.1M Buy
120,644
+14,486
+14% +$1.8M ﹤0.01% 2609
2017
Q1 		$13.1M Buy
106,158
+16,015
+18% +$2.1M ﹤0.01% 2634
2016
Q4 		$12.3M Buy
90,143
+2,638
+3% +$468K ﹤0.01% 2653
2016
Q3 		$17.4M Buy
87,505
+12,347
+16% +$2.13M ﹤0.01% 2424
2016
Q2 		$9.74M Buy
75,158
+6,434
+9% +$716K ﹤0.01% 2662
2016
Q1 		$6.42M Buy
68,724
+3,156
+5% +$344K ﹤0.01% 2835
2015
Q4 		$13.3M Buy
65,568
+6,656
+11% +$1.19M ﹤0.01% 2482
2015
Q3 		$8.56M Buy
58,912
+30,897
+110% +$5.67M ﹤0.01% 2686
2015
Q2 		$5.96M Buy
28,015
+6,098
+28% +$1.49M ﹤0.01% 2924
2015
Q1 		$5.08M Buy
21,917
+15,417
+237% +$3.73M ﹤0.01% 2995
2014
Q4 		$1.5M Buy
+6,500
New +$1.39M ﹤0.01% 3379

Other funds holding BLCM

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Vanguard Group's BLCM Position: Q2 2023 in Review

Vanguard Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 66,309 shares — an estimated $21.9K sold.

Vanguard Group first reported a position in BLCM in Q4 2014 and held it in 34 quarters. The position peaked at $17.4M in Q3 2016. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

  • Vanguard Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Vanguard Group sold 66,309 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $21.9K.
  • Vanguard Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 34 quarters.
  • Vanguard Group's Bellicum Pharmaceuticals, Inc. position peaked at $17.4M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.